Compile Data Set for Download or QSAR

Found 11 hits Enz. Inhib. hit(s) with Target = 'Mu-type opioid receptor' and Ligand = 'BDBM179891'   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Mu-type opioid receptor (Homo sapiens (Human))	BDBM179891 (US10287250, Compound C.9 | US10752592, Compound TA...) Show SMILES Oc1c(ccc2C[C@H]3N(CC4CC4)CC[C@@]4(CC(=O)CC[C@@]34O)c12)C(=O)NCCc1ccc(cc1)-c1cccnc1 |r| Show InChI InChI=1S/C34H37N3O4/c38-27-11-13-34(41)29-18-25-9-10-28(31(39)30(25)33(34,19-27)14-17-37(29)21-23-3-4-23)32(40)36-16-12-22-5-7-24(8-6-22)26-2-1-15-35-20-26/h1-2,5-10,15,20,23,29,39,41H,3-4,11-14,16-19,21H2,(H,36,40)/t29-,33-,34-/m1/s1	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	0.370	-53.8	1.5	n/a	n/a	n/a	n/a	7.5	25
ALKERMES PHARMA IRELAND LIMITED US Patent					Assay Description The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal o...				US Patent US9133125 (2015) BindingDB Entry DOI: 10.7270/Q2736PPB
					More data for this Ligand-Target Pair
Mu-type opioid receptor (Homo sapiens (Human))	BDBM179891 (US10287250, Compound C.9 | US10752592, Compound TA...) Show SMILES Oc1c(ccc2C[C@H]3N(CC4CC4)CC[C@@]4(CC(=O)CC[C@@]34O)c12)C(=O)NCCc1ccc(cc1)-c1cccnc1 |r| Show InChI InChI=1S/C34H37N3O4/c38-27-11-13-34(41)29-18-25-9-10-28(31(39)30(25)33(34,19-27)14-17-37(29)21-23-3-4-23)32(40)36-16-12-22-5-7-24(8-6-22)26-2-1-15-35-20-26/h1-2,5-10,15,20,23,29,39,41H,3-4,11-14,16-19,21H2,(H,36,40)/t29-,33-,34-/m1/s1	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	0.370	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Bristol-Myers Squibb Company					Assay Description The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...				Bioorg Med Chem Lett 17: 4284-9 (2007) BindingDB Entry DOI: 10.7270/Q2125W08
					More data for this Ligand-Target Pair
Mu-type opioid receptor (Homo sapiens (Human))	BDBM179891 (US10287250, Compound C.9 | US10752592, Compound TA...) Show SMILES Oc1c(ccc2C[C@H]3N(CC4CC4)CC[C@@]4(CC(=O)CC[C@@]34O)c12)C(=O)NCCc1ccc(cc1)-c1cccnc1 |r| Show InChI InChI=1S/C34H37N3O4/c38-27-11-13-34(41)29-18-25-9-10-28(31(39)30(25)33(34,19-27)14-17-37(29)21-23-3-4-23)32(40)36-16-12-22-5-7-24(8-6-22)26-2-1-15-35-20-26/h1-2,5-10,15,20,23,29,39,41H,3-4,11-14,16-19,21H2,(H,36,40)/t29-,33-,34-/m1/s1	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	0.370	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
ALKERMES PHARMA IRELAND LIMITED US Patent					Assay Description The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...				US Patent US10752592 (2020) BindingDB Entry DOI: 10.7270/Q23R0WX0
					More data for this Ligand-Target Pair
Mu-type opioid receptor (Homo sapiens (Human))	BDBM179891 (US10287250, Compound C.9 | US10752592, Compound TA...) Show SMILES Oc1c(ccc2C[C@H]3N(CC4CC4)CC[C@@]4(CC(=O)CC[C@@]34O)c12)C(=O)NCCc1ccc(cc1)-c1cccnc1 |r| Show InChI InChI=1S/C34H37N3O4/c38-27-11-13-34(41)29-18-25-9-10-28(31(39)30(25)33(34,19-27)14-17-37(29)21-23-3-4-23)32(40)36-16-12-22-5-7-24(8-6-22)26-2-1-15-35-20-26/h1-2,5-10,15,20,23,29,39,41H,3-4,11-14,16-19,21H2,(H,36,40)/t29-,33-,34-/m1/s1	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	0.370	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
ALKERMES PHARMA IRELAND LIMITED US Patent					Assay Description The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...				US Patent US9656961 (2017) BindingDB Entry DOI: 10.7270/Q2PR7Z13
					More data for this Ligand-Target Pair
Mu-type opioid receptor (Homo sapiens (Human))	BDBM179891 (US10287250, Compound C.9 | US10752592, Compound TA...) Show SMILES Oc1c(ccc2C[C@H]3N(CC4CC4)CC[C@@]4(CC(=O)CC[C@@]34O)c12)C(=O)NCCc1ccc(cc1)-c1cccnc1 |r| Show InChI InChI=1S/C34H37N3O4/c38-27-11-13-34(41)29-18-25-9-10-28(31(39)30(25)33(34,19-27)14-17-37(29)21-23-3-4-23)32(40)36-16-12-22-5-7-24(8-6-22)26-2-1-15-35-20-26/h1-2,5-10,15,20,23,29,39,41H,3-4,11-14,16-19,21H2,(H,36,40)/t29-,33-,34-/m1/s1	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	1.5	n/a	n/a	n/a	n/a	n/a	n/a
ALKERMES PHARMA IRELAND LIMITED US Patent					Assay Description The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...				US Patent US9656961 (2017) BindingDB Entry DOI: 10.7270/Q2PR7Z13
					More data for this Ligand-Target Pair
Mu-type opioid receptor (Homo sapiens (Human))	BDBM179891 (US10287250, Compound C.9 | US10752592, Compound TA...) Show SMILES Oc1c(ccc2C[C@H]3N(CC4CC4)CC[C@@]4(CC(=O)CC[C@@]34O)c12)C(=O)NCCc1ccc(cc1)-c1cccnc1 |r| Show InChI InChI=1S/C34H37N3O4/c38-27-11-13-34(41)29-18-25-9-10-28(31(39)30(25)33(34,19-27)14-17-37(29)21-23-3-4-23)32(40)36-16-12-22-5-7-24(8-6-22)26-2-1-15-35-20-26/h1-2,5-10,15,20,23,29,39,41H,3-4,11-14,16-19,21H2,(H,36,40)/t29-,33-,34-/m1/s1	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	1.5	n/a	n/a	n/a	n/a	n/a	n/a
ALKERMES PHARMA IRELAND LIMITED US Patent					Assay Description The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...				US Patent US10752592 (2020) BindingDB Entry DOI: 10.7270/Q23R0WX0
					More data for this Ligand-Target Pair
Mu-type opioid receptor (Homo sapiens (Human))	BDBM179891 (US10287250, Compound C.9 | US10752592, Compound TA...) Show SMILES Oc1c(ccc2C[C@H]3N(CC4CC4)CC[C@@]4(CC(=O)CC[C@@]34O)c12)C(=O)NCCc1ccc(cc1)-c1cccnc1 |r| Show InChI InChI=1S/C34H37N3O4/c38-27-11-13-34(41)29-18-25-9-10-28(31(39)30(25)33(34,19-27)14-17-37(29)21-23-3-4-23)32(40)36-16-12-22-5-7-24(8-6-22)26-2-1-15-35-20-26/h1-2,5-10,15,20,23,29,39,41H,3-4,11-14,16-19,21H2,(H,36,40)/t29-,33-,34-/m1/s1	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	1.5	n/a	n/a	n/a	n/a	n/a	n/a
Bristol-Myers Squibb Company					Assay Description The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...				Bioorg Med Chem Lett 17: 4284-9 (2007) BindingDB Entry DOI: 10.7270/Q2125W08
					More data for this Ligand-Target Pair
Mu-type opioid receptor (Homo sapiens (Human))	BDBM179891 (US10287250, Compound C.9 | US10752592, Compound TA...) Show SMILES Oc1c(ccc2C[C@H]3N(CC4CC4)CC[C@@]4(CC(=O)CC[C@@]34O)c12)C(=O)NCCc1ccc(cc1)-c1cccnc1 |r| Show InChI InChI=1S/C34H37N3O4/c38-27-11-13-34(41)29-18-25-9-10-28(31(39)30(25)33(34,19-27)14-17-37(29)21-23-3-4-23)32(40)36-16-12-22-5-7-24(8-6-22)26-2-1-15-35-20-26/h1-2,5-10,15,20,23,29,39,41H,3-4,11-14,16-19,21H2,(H,36,40)/t29-,33-,34-/m1/s1	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	2.90	n/a	n/a	n/a	n/a
Bristol-Myers Squibb Company					Assay Description The EC50 and Imax for μ opioid receptors was determined using a [35S]GTPγS binding assay. This assay measures the functional properties of ...				Bioorg Med Chem Lett 17: 4284-9 (2007) BindingDB Entry DOI: 10.7270/Q2125W08
					More data for this Ligand-Target Pair
Mu-type opioid receptor (Homo sapiens (Human))	BDBM179891 (US10287250, Compound C.9 | US10752592, Compound TA...) Show SMILES Oc1c(ccc2C[C@H]3N(CC4CC4)CC[C@@]4(CC(=O)CC[C@@]34O)c12)C(=O)NCCc1ccc(cc1)-c1cccnc1 |r| Show InChI InChI=1S/C34H37N3O4/c38-27-11-13-34(41)29-18-25-9-10-28(31(39)30(25)33(34,19-27)14-17-37(29)21-23-3-4-23)32(40)36-16-12-22-5-7-24(8-6-22)26-2-1-15-35-20-26/h1-2,5-10,15,20,23,29,39,41H,3-4,11-14,16-19,21H2,(H,36,40)/t29-,33-,34-/m1/s1	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	2.90	n/a	n/a	n/a	n/a
ALKERMES PHARMA IRELAND LIMITED US Patent					Assay Description The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...				US Patent US9656961 (2017) BindingDB Entry DOI: 10.7270/Q2PR7Z13
					More data for this Ligand-Target Pair
Mu-type opioid receptor (Homo sapiens (Human))	BDBM179891 (US10287250, Compound C.9 | US10752592, Compound TA...) Show SMILES Oc1c(ccc2C[C@H]3N(CC4CC4)CC[C@@]4(CC(=O)CC[C@@]34O)c12)C(=O)NCCc1ccc(cc1)-c1cccnc1 |r| Show InChI InChI=1S/C34H37N3O4/c38-27-11-13-34(41)29-18-25-9-10-28(31(39)30(25)33(34,19-27)14-17-37(29)21-23-3-4-23)32(40)36-16-12-22-5-7-24(8-6-22)26-2-1-15-35-20-26/h1-2,5-10,15,20,23,29,39,41H,3-4,11-14,16-19,21H2,(H,36,40)/t29-,33-,34-/m1/s1	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	2.90	n/a	n/a	n/a	n/a
ALKERMES PHARMA IRELAND LIMITED US Patent					Assay Description The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...				US Patent US10752592 (2020) BindingDB Entry DOI: 10.7270/Q23R0WX0
					More data for this Ligand-Target Pair
Mu-type opioid receptor (Homo sapiens (Human))	BDBM179891 (US10287250, Compound C.9 | US10752592, Compound TA...) Show SMILES Oc1c(ccc2C[C@H]3N(CC4CC4)CC[C@@]4(CC(=O)CC[C@@]34O)c12)C(=O)NCCc1ccc(cc1)-c1cccnc1 |r| Show InChI InChI=1S/C34H37N3O4/c38-27-11-13-34(41)29-18-25-9-10-28(31(39)30(25)33(34,19-27)14-17-37(29)21-23-3-4-23)32(40)36-16-12-22-5-7-24(8-6-22)26-2-1-15-35-20-26/h1-2,5-10,15,20,23,29,39,41H,3-4,11-14,16-19,21H2,(H,36,40)/t29-,33-,34-/m1/s1	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	2.90	n/a	n/a	7.4	n/a
ALKERMES PHARMA IRELAND LIMITED US Patent					Assay Description The EC50 and Imax for μ opioid receptors was determined using a [I35S]GTPγS binding assay. This assay measures the functional properties of a compo...				US Patent US9133125 (2015) BindingDB Entry DOI: 10.7270/Q2736PPB
					More data for this Ligand-Target Pair